+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 37 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Researchers are evaluating a new schedule of alternating cycles of chemoimmunotherapy chemotherapy plus pembrolizumab and immunotherapy pembrolizumab alone as the first treatment for patients with advanced lung or head and neck cancers. This phase II study aims to see if less frequent chemotherapy during the induction phase can effectively control the cancer while preserving quality of life. The trial also monitors safety and response rates over time. The study has three groups based on cancer type. Each group receives alternating cycles combination chemoimmunotherapy cycles consisting of drugs like carboplatin, paclitaxel, pemetrexed, or 5-fluorouracil with pembrolizumab, followed by cycles of pembrolizumab alone. The number of cycles varies by group, with up to four or six cycles during induction. After induction, maintenance therapy with pembrolizumab alone or combined with pemetrexed continues for up to two years. Participants will have regular assessments including imaging and laboratory tests before and during treatment to measure tumor response and monitor side effects. Researchers will track how many patients complete the induction therapy cycles and evaluate overall response rates at 6 weeks. Safety is monitored throughout the study, which can last up to three years for progression and adverse event follow-up. Patients will provide informed consent and be closely monitored during the trial.

Age: 18Years +All GendersPhase 2
11 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are studying muscle invasive bladder cancer to see if combining pembrolizumab, a type of immunotherapy, with radiation therapy after chemotherapy can help patients avoid bladder removal surgery. This phase II trial focuses on patients who have responded well to initial chemotherapy and aims to improve three-year bladder intact event-free survival. The study also evaluates survival rates, recurrence, and treatment side effects in participants. Participants receive photon beam radiation therapy once daily from Monday to Friday for up to 20 treatments. Pembrolizumab is given intravenously on the first day of each 21-day cycle, continuing for up to 18 cycles or about 12 months if there is no disease progression or unacceptable side effects. Before treatment, participants undergo a transurethral resection of bladder tumor TURBT and provide tissue samples. Imaging scans such as CT, MRI, or PET, along with cystoscopy and collection of urine and blood samples, are performed throughout the study. During the study, participants are closely monitored with regular assessments including imaging and questionnaires about symptoms. Follow-up visits occur every 26 weeks until two years after treatment and then annually up to five years. Researchers measure outcomes like bladder intact event-free survival, local recurrence, metastasis-free survival, overall survival, and rates of salvage cystectomy. Safety and treatment-related symptoms are tracked carefully, and specimens are collected for future research.

Age: 18Years +All GendersPhase 2
182 locations
E

Actively Recruiting

Researchers are evaluating treatment options for younger patients with intermediate risk acute myeloid leukemia AML in this phase II trial. The study compares three different drug combinations cytarabine with daunorubicin cytarabine with daunorubicin plus venetoclax and venetoclax with azacitidine. The goal is to see if adding venetoclax improves the elimination of leukemia cells compared to the usual treatment, by measuring undetectable residual disease after therapy. Participants are randomly assigned to one of three treatment groups. One group receives daunorubicin and cytarabine with venetoclax over 28-day cycles, possibly followed by reinduction therapy based on bone marrow assessments. The second group receives azacitidine combined with venetoclax for two 28-day cycles. The third group receives daunorubicin and cytarabine alone, with potential reinduction treatment. Patients undergo bone marrow aspiration, blood sample collection, and heart function tests before and during the study. During the trial, participants will have regular evaluations including bone marrow tests and blood draws to monitor treatment effects and disease status. Heart function is assessed at screening with echocardiography or a MUGA scan. After completing treatment, patients are followed with visits at 4 weeks, every 3 months for the first year, every 6 months in the second year, and yearly thereafter. Researchers track remission rates, toxicities, survival outcomes, and responses based on genetic features for up to 10 years.

Age: 18Years - 59YearsAll GendersPhase 2
187 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining ASTX727 and venetoclax with or without enasidenib in treating older adults newly diagnosed with acute myeloid leukemia AML who have a mutation in the IDH2 gene. This phase II trial aims to see if adding enasidenib to the usual treatment can improve outcomes by reducing measurable residual disease-negative complete remission rates in patients who are either older or unfit for standard therapy. Participants are randomly assigned to one of two treatment groups. One group receives oral ASTX727 daily on days 1-5 and venetoclax daily on days 1-28 of each 28-day cycle. The other group receives the same treatment plus oral enasidenib daily on days 1-28. Treatment cycles continue every 28 days unless disease progression or unacceptable side effects occur. Throughout the trial, blood samples, bone marrow aspirations, and biopsies are collected to monitor disease and treatment effects. During the study, participants undergo regular evaluations including blood tests and bone marrow procedures to assess remission status and measurable residual disease. After completing treatment, participants are followed monthly for the first year, then every two months in the second year, every three months in the third year, and every six months up to five years or until death. Researchers measure remission rates, survival outcomes, and adverse events to understand the treatments impact on AML with IDH2 mutation.

Age: 18Years +All GendersPhase 2
138 locations
R

Actively Recruiting

Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.

Age: 18Years +All GendersPhase 3
288 locations
R

Actively Recruiting

Researchers are evaluating the treatment of older adults aged 75 and above with early-stage cutaneous melanoma. The study compares the effectiveness of wide local excision WLE alone to the usual care of WLE combined with sentinel lymph node SLN biopsy. The main goal is to see if the less invasive WLE alone can provide similar results in preventing melanoma recurrence. This phase III trial also aims to assess patient-reported outcomes and the impact of geriatric assessments on treatment results. Participants are randomly assigned to one of two groups one group receives WLE plus SLN biopsy, and the other group receives WLE alone. Both groups may undergo surveillance of the lymph node area and receive additional treatments called adjuvant therapies if needed. Throughout the study, participants may have imaging tests such as computed tomography CT, positron emission tomography PETCT, or ultrasound. After initial treatment, patients are monitored closely with regular follow-ups. During the study, participants will be followed every four months for two years and then every six months up to five years after randomization. Researchers will collect data on recurrence-free survival, overall survival, melanoma-specific survival, safety, and patient quality of life. The study also involves comprehensive geriatric assessments and questionnaires to evaluate physical and functional status. These measures will help develop tools to predict risks and guide future surgical decisions for older adults with melanoma.

Age: 75Years +All GendersPhase 3
181 locations

1-10 of 37

1